Subscribe
shutterstock_521453077_rolandmagnusson
Roland Magnusson / Shutterstock.com
2 April 2019Big Pharma

AstraZeneca and Daiichi Sankyo to develop new cancer treatment

Biopharmaceutical company  AstraZeneca has entered into an agreement with Japanese pharmaceutical company  Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
AstraZeneca to launch CRISPR-based cancer research centre
11 December 2018   Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.
Big Pharma
Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
14 November 2019   Seattle Genetics has asked the American Arbitration Association to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.
Americas
Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12 February 2020   American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Biotechnology
AstraZeneca to launch CRISPR-based cancer research centre
11 December 2018   Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.
Big Pharma
Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
14 November 2019   Seattle Genetics has asked the American Arbitration Association to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.
Americas
Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12 February 2020   American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.

More on this story

Biotechnology
AstraZeneca to launch CRISPR-based cancer research centre
11 December 2018   Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.
Big Pharma
Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
14 November 2019   Seattle Genetics has asked the American Arbitration Association to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.
Americas
Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12 February 2020   American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.

More features

UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Bristol Myers Squibb leader named INTA 2025 president
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks